<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01748331</url>
  </required_header>
  <id_info>
    <org_study_id>H-1-2012-060</org_study_id>
    <nct_id>NCT01748331</nct_id>
  </id_info>
  <brief_title>The Effect of Fluid Restriction in Congestive Heart Failure Complicated With Hyponatremia</brief_title>
  <acronym>Decongest</acronym>
  <official_title>The Significance of the Vasopressin System of the Hemodynamics, Water Balance and Prognosis in Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Finn Gustafsson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of fluid restriction and the&#xD;
      neurohormonal mechanisms in the development of hyponatremia in patients with congestive heart&#xD;
      failure and hyponatremia. The hypothesis is that strict fluid restriction leads to a larger&#xD;
      increase in plasma sodium than standard treatment in patients with decompensated heart&#xD;
      failure associated with hyponatremia. A secondary hypothesis is that the neurohormonal change&#xD;
      is greater in patients treated with strict fluid restriction versus standard treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma sodium from day 1 to day 4: - Normalization of plasma sodium or - A significant change in plasma sodium of a minimum of 5 mmol/L from baseline to day 4</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma vasopressin and copeptin</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure, heart rate, weight and oedemas</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dyspnoea assessed by the patient</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days until clinical stability</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correlation between hospitalization time and plasma sodium</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between fluid restriction and change in kidney function</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient assessment of fluid restriction</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient compliance to fluid restriction</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure</condition>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>Strict fluid restriction &lt; 1 L/day</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>20 patients will be randomized to strict fluid restriction &lt; 1 L/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate fluid restriction &lt; 2.5 L/day</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>20 patients will be randomized to moderate fluid restriction &lt; 2.5 L/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluid restriction</intervention_name>
    <description>Patients will be randomized to strict fluid restriction &lt; 1 L/day versus moderate fluid restriction &lt; 2.5 L/day</description>
    <arm_group_label>Moderate fluid restriction &lt; 2.5 L/day</arm_group_label>
    <arm_group_label>Strict fluid restriction &lt; 1 L/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction (LVEF) &lt; 40&#xD;
&#xD;
        At least two of the following signs of decompensated heart failure and fluid retention:&#xD;
&#xD;
          -  Weight gain &gt; 2 kg&#xD;
&#xD;
          -  Pulmonal Congestion&#xD;
&#xD;
          -  Jugular vein congestion&#xD;
&#xD;
          -  Peripheral oedemas&#xD;
&#xD;
          -  Hepatic congestion with ascites&#xD;
&#xD;
          -  Radiographic signs of fluid retention&#xD;
&#xD;
          -  Increased diuretic dose&#xD;
&#xD;
        And&#xD;
&#xD;
          -  New York Heart Association (NYHA) class III-IV&#xD;
&#xD;
          -  Plasma sodium &lt; 135 mmol/L&#xD;
&#xD;
          -  Symptomatic heart failure and treatment with relevant heart failure medications&#xD;
             (beta-blocker, diuretic, digoxin, angiotensin-converting-enzyme inhibitor,&#xD;
             angiotensin-II receptor antagonist, spironolactone, hydralazine and/or nitrates)for at&#xD;
             least 1 month&#xD;
&#xD;
          -  Hospitalization for decompensated heart failure within the last 48 hours&#xD;
&#xD;
          -  Given informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Plasma sodium ≥ 135 mmol/L before randomization&#xD;
&#xD;
          -  Reduced kidney function (creatinine &gt; 200 μmol/L)&#xD;
&#xD;
          -  Severe hematologic disease&#xD;
&#xD;
          -  Hypovolemic hyponatremia (volume depletion or dehydration)&#xD;
&#xD;
          -  Intolerability to large or fast changes in fluid volume assessed by the investigator&#xD;
&#xD;
          -  Plasma sodium &lt; 120 mmol/L accompanied by neurologic symptoms&#xD;
&#xD;
          -  Anuria&#xD;
&#xD;
          -  Symptomatic systolic blood pressure (supine systolic blood pressure &lt; 90 mmHg)&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure &gt; 180 mmHg)&#xD;
&#xD;
          -  Uncontrolled diabetes diabetes mellitus&#xD;
&#xD;
          -  Adrenal insufficiency&#xD;
&#xD;
          -  Acute myocardial infarction, sustained ventricular tachycardia or ventricular&#xD;
             fibrillation within the last 30 days&#xD;
&#xD;
          -  Heart surgery within the last 60 days&#xD;
&#xD;
          -  Other severe heart disease: hypertrophic cardiomyopathy, severe heart valve disease,&#xD;
             cardiac amyloidosis, active myocarditis, pericardial exudate which is hemodynamically&#xD;
             significant&#xD;
&#xD;
          -  Left ventricular assist device (LVAD)&#xD;
&#xD;
          -  Planned revascularization procedure, electrophysiologic device implantation, mechanic&#xD;
             left ventricular assist device, heart transplant or any other heart surgery procedures&#xD;
             within the next 30 days&#xD;
&#xD;
          -  Cerebrovascular event within the last 6 months&#xD;
&#xD;
          -  Comorbidity with an expected survival &lt; 6 months&#xD;
&#xD;
          -  Other reasons for hyponatremia: Primary syndrome of inappropriate antidiuretic hormone&#xD;
             secretion (SIADH), primary polydipsia, head trauma, uncontrolled hypothyroidism,&#xD;
             adrenal insufficiency or other known pharmacologically triggered hyponatremia which is&#xD;
             reversible upon discontinuation of the drug, hyperglycemia (pseudohyponatremia),&#xD;
             present abuse of alcohol&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Pregnant or fertile women who are not using safe contraception&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Unwilling or unable to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Finn Gustafsson, MD, PhD, DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Finn Gustafsson, MD, PhD, DMSci</last_name>
    <phone>004535459743</phone>
    <email>finn.gustafsson@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louise Balling, MD</last_name>
    <phone>004523451679</phone>
    <email>louise.balling@dadlnet.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiology, Copenhagen University Hospital, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>1718</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Finn Gustafsson, MD, PhD, DMSci</last_name>
      <phone>004535459743</phone>
      <email>finn.gustafsson@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Louise Balling, MD</last_name>
      <phone>004523451679</phone>
      <email>louise.balling@dadlnet.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Finn Gustafsson, MD, PhD, DMSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louise Balling, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olav Wendelboe Nielsen, MD, DMSc</last_name>
      <phone>004535316448</phone>
      <email>owen0002@bbh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Olav W Nielsen, MD, DMSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>December 10, 2012</study_first_submitted>
  <study_first_submitted_qc>December 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2012</study_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Finn Gustafsson</investigator_full_name>
    <investigator_title>Staff Cardiologist, PhD, DMSci</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Hyponatremia</keyword>
  <keyword>Fluid restriction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

